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undertaken laparoscopically and the robot
used for dismemberment and anastomosis.
Results: Five of the six had their surgery
completed robotically; open conversion was
required in the patient who had undergone
previous open pyeloplasty, the same patient
required a blood transfusion due to haemo-
lysis. Other surgical parameters (length of
stay, operating time, complications, return
to normal activities) were all in an accept-
able range. Six month postoperative nuc-
lear renography revealed no obstruction in
any patient and all were asymptomatic.
Conclusion: Robotic assisted pyeloplasty is
technically feasible for the surgeon with lit-
tle experience of laparoscopic suturing.
Operative data and early follow-up results
are encouraging.
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Objective: To determine if local anaesthetic
reduces patient discomfort following
laparoscopic urological surgery.
Methods: Sixty-seven patients undergoing
laparoscopic urological surgery were ran-
domly assigned to either the treatment
(0.5% bupivacaine) arm or the placebo
(0.9% normal saline) arm. Patients, surgeon
and data collector were blinded. The port
sites and the hand assist port site (when
present) were infiltrated at the outset of
the procedure. Postoperative pain was
determined with a standardized 10 point
visual analog scale at consistent intervals.
Results: Thirty-three individuals were trea-
ted with the placebo (13 standard laparo-
scopic [SL] and 20 hand assisted
laparoscopic [HALS]) and 34 with bupiva-
caine (17 SL and 17 HALS). Average pain
scores for the placebo vs. bupivacaine group
at 4, 12, 24 h were 3.9, 3.1, 3.6 vs. 3.0, 2.1,
2.0 (P < 0.10). Mean use of morphine for
the placebo group vs. bupivacaine group
was: 26.1 mg (range 0–91.9) vs. 15.4 mg
(range 0–49.5) at 12 h (P < 0.05), 43.5 mg
(range 0–136.9) vs. 26.2 mg (range 0–71.0)
at 24 h (P = 0.07) and 50.4 mg (range 0–
154.9) vs. 28.3 mg (range 0–71.0) for total
hospital stay (P < 0.05). In multivariable ANO-
VA, use of bupivacaine, but not SL vs. HALS,
was associated with reduced morphine use
at all three time points (P < 0.05).
Conclusions: At the outset of laparoscopic
urological surgery in the upper retroperito-
neum, port site and other incision infiltration
with a long acting local anaesthetic reduces
postoperative parenteral opioid requirements
when compared with placebo controls.
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Introduction and Objective: Open radical
prostatectomy is a difficult and complex
operation to teach residents. Many patient
factors can increase the complexity of the
operation, with the majority not being pre-
dictable prior to the operation. We hypothe-
sised that large prostate glands (>75 cc)
would result in increased difficulty, higher in-
traoperative complications, and subsequently
poorer cancer and functional outcomes.
Methods: A retrospective analysis of the
records of patients in our database of rad-
ical prostatectomies performed at West-
mead Hospital. Patients operated on by the
training urology registrar were identified
and further analysed. Intraoperative as well
as postoperative complications, pathology
results and postoperative gain of potency
and continence were evaluated.
Results: Between 2/6/1998 to 14/8/04, 181
open radical prostatectomies were per-
formed at Westmead Public Hospital by the
training registrar. Preoperative variables
revealed that the majority of these patients
had large volume cancer (171 pts with cT2
cancer, 70 pts with Gleason Score ‡7). PSA
ranged from 1.2–27 ng/ml (median 6.9 ng/
ml). Prostate size ranged from 11–112 cc
(median 31 cc) measured by TRUS ultra-
sound. Correlation between calculated TRUS
volume and prostate weight at surgery was
high (r = 0.93). Prostate glands greater
than 75 cc were associated with older age
(P = 0.001), longer operation time
(P < 0.001)and higher estimated blood loss
(P < 0.001). Postoperatively, prostate glands
>75 cc required median of 7 vs 3 months
to achieve continence (P < 0.001). At a
median follow time of 45 months, men
with prostates <75 cc had a 62% chance
of achieving potency compared to 10% of
men who has glands >75cc (P < 0.001).
Oncologically, larger prostates had less
positive surgical margins (P = 0.006) and
less PSA recurrence (P = 0.024).
Conclusions: Prostates larger than 75 cc
result in longer operative times, higher
blood loss as well as poorer continence and
potency. Patients should be counselled
accordingly and trainers should be prepared
to supervise more carefully when teaching
inexperienced trainees.
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Introduction: Removal of a large prostate
can be challenging during open or laparo-
scopic radical prostatectomy (LRP).
Although gland size has been shown not to
influence functional outcome in open
radical prostatectomy (ORP) (Foley, 2003),
longer operating times have been reported
for transperitoneal LRP (El-Feel, 2003;
Rassweiler, 2001). The aim of this study
was to investigate the influence of prostate
size on LRP outcomes.
Patients and Methods: Four hundred cases
of LRP were performed. 111 LRP were per-
formed using a transperitoneal approach
and 289 using an extraperitoneal approach.
319 patients had a prostate weight £75 g
and 81 patients had a prostate weight
‡75 g on final histology.
Results: Patients’ age, weight, PSA, Gleason
sum and clinical stage were all similar. Val-
ues are mean; 1independent samples test;
2Chi-square test.








(days) 2Compl 2+ margins
Prostate <75 g 46.8 192 259 3.2 4.5% 21.5%
Prostate >75 g 97.8 207 289 2.9 10.5% 9.3%
P <0.0001 0.03 0.25 0.04 0.07 0.03
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